By: Justin Hay & Frank Engler
Pandemics amplify existing strengths and vulnerabilities—not only highlighting who are among the at-risk populations in our society, but also bringing to prominence strengths and weaknesses within healthcare systems and drug development processes. Advancements in vaccines and antivirals were carried out at unprecedented speed during the COVID-19 pandemic using exciting, new technologies, and there are now a slew of enquiries, reports, and (hopefully) “lessons learned” from those experiences. But is dose optimization one of these teachings?
To read the full issue of Clinical Researcher click here.
